N-piperidine Ibrutinib hydrochloride
98%
- Product Code: 55178
CAS:
2231747-18-3
| Molecular Weight: | 422.91 g./mol | Molecular Formula: | C₂₂H₂₃ClN₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, protected from light |
Product Description:
N-piperidine Ibrutinib hydrochloride is primarily used in the field of oncology, specifically for the treatment of certain types of cancers. It is a modified form of Ibrutinib, which is a well-known Bruton's tyrosine kinase (BTK) inhibitor. This compound is particularly effective in targeting and inhibiting BTK, a key enzyme involved in the signaling pathways of B-cell malignancies.
One of the main applications of N-piperidine Ibrutinib hydrochloride is in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, it disrupts the survival and proliferation signals in cancerous B-cells, leading to their apoptosis. This makes it a valuable therapeutic option for patients with these types of cancers, especially those who have not responded well to other treatments.
Additionally, N-piperidine Ibrutinib hydrochloride is being investigated for its potential use in other B-cell malignancies and autoimmune diseases. Its ability to modulate B-cell activity makes it a promising candidate for conditions where B-cell dysfunction plays a critical role.
Overall, N-piperidine Ibrutinib hydrochloride represents a significant advancement in targeted cancer therapy, offering hope for improved outcomes in patients with difficult-to-treat cancers.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿19,800.00 |
+
-
|
| 0.010 | 10-20 days | ฿34,560.00 |
+
-
|
N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride is primarily used in the field of oncology, specifically for the treatment of certain types of cancers. It is a modified form of Ibrutinib, which is a well-known Bruton's tyrosine kinase (BTK) inhibitor. This compound is particularly effective in targeting and inhibiting BTK, a key enzyme involved in the signaling pathways of B-cell malignancies.
One of the main applications of N-piperidine Ibrutinib hydrochloride is in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, it disrupts the survival and proliferation signals in cancerous B-cells, leading to their apoptosis. This makes it a valuable therapeutic option for patients with these types of cancers, especially those who have not responded well to other treatments.
Additionally, N-piperidine Ibrutinib hydrochloride is being investigated for its potential use in other B-cell malignancies and autoimmune diseases. Its ability to modulate B-cell activity makes it a promising candidate for conditions where B-cell dysfunction plays a critical role.
Overall, N-piperidine Ibrutinib hydrochloride represents a significant advancement in targeted cancer therapy, offering hope for improved outcomes in patients with difficult-to-treat cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :